Drugs / Eftozanermin alfa
Eftozanermin alfa
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04570631 | Nov 2020 → May 2025 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT03082209 | Mar 2017 → Jan 2022 | cancer, hematopoietic and lymphoid cell neoplasm | AbbVie | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eftozanermin alfa | “Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.” PMID 35467243 ↗ Apr 2022 |
| Known as | ABBV-621 | “Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.” PMID 35467243 ↗ Apr 20221“Eftozanermin alfa (ABBV-621) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM).” NCT04570631 ↗ |
| Known as | Eftozanermina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594322 ↗ |
| Known as | Eftozanermine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594322 ↗ |
| Action | Activate | “a second-generation tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist” PMID 38036720 ↗ Nov 2023 |
| Modality | Protein / enzyme biologic | “TRAIL receptor agonistic fusion protein eftozanermin alfa” PMID 36720090 ↗ Apr 2023 |
| Route | Intravenous | “Eftozanermin alfa is a second-generation tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist that enhances death receptor 4/5 clustering on tumor...” PMID 38036720 ↗ Nov 2023 |